Prevalence of CASR rs1042636 Polymorphisms in Thai Hemodialysis Patients
Article Sidebar
Main Article Content
Abstract
Objective: To determine the prevalences of the variant genotypes and allele frequencies of CASR rs1042636 in Thai hemodialysis patients and to compare the observed allele frequencies with those reported in other ethnic populations. Methods: This was an observational study in patients receiving hemodialysis at King Chulalongkorn Memorial Hospital, having secondary hyperparathyroidism (SHPT), and being prescribed cinacalcet for the first time during Jan 2005-May 2019. CASR rs1042636 polymorphism was identified by the TaqMan genotyping assay. The study compared the observed allele frequencies among Thai to those in other population previously reported. Results: A total of 126 patients participated in this study. The observed prevalences of AA, AG, and GG genotypes were 23.0%, 29.4%, and 47.6%, respectively. The allele A and allele G frequencies were 46.8% and 53.2%, respectively. There were no significant differences between the allele frequencies of CASR rs1042636 observed in our studied population and those reported in other Asian populations, including Japanese, Chinese, and Korean (P=0.339, 0.901, and 0.850, respectively), but significant differences were observed when compared with those reported among Caucasians and African Americans. Allele A frequencies in Thais were significantly lower than in Caucasians and African Americans (P<0.001). Conclusion: In Thai hemodialysis patients, prevalence of CASR rs1042636 genetic polymorphisms was comparable to those observed in other Asian populations but was significantly different from those reported among Caucasians and African Americans.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-64.
Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999;106: 238-53.
Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005; 42: 35-70.
Riccardi D, Brown EM. Physiology and pathophysio logy of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010; 298: F485-99.
Chattopadhyay N, Mithal A, Brown EM. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 1996; 17: 289-307.
Thakker R. Calcium-sensing receptor: Role in health and disease. Indian J Endocrinol Metab 2012; 16 (Suppl 2): S213-6.
Vahe C, Benomar K, Espiard S, Coppin L, Jannin A, Odou M, et al. Diseases associated with calcium-sensing receptor. Orphanet J Rare Dis 2017; 12: 19-27.
Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Front Physiol 2016; 7: 563-75
Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201.
Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-58.
Sutheechai S, Sudchada P. Mineral and bone disorder in chronic kidney disease. Srinagarind Medical Journal 2012; 27: 415-23.
Yano S, Sugimoto T, Kanzawa M, Tsukamoto T, Hattori T, Hattori S, et al. Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patients. Nephron 2000; 85: 317-23.
Yamauchi M, Sugimoto T, Yamaguchi T, Yano S, Kanzawa M, Kobayashi A, et al. Association of polymorphic alleles of the calcium-sensing receptor gene with the clinical severity of primary hyperparathyroidism. Clin Endocrinol (Oxf) 2001; 55: 373-9.
Rohlfs RV, Weir BS. Distributions of Hardy–Weinberg equilibrium test statistics. Genetics 2008; 180: 609-16.
Corbetta S, Eller-Vainicher C, Filopanti M, Saeli P, Vezzoli G, Arcidiacono T, et al. R990G polymorphism of the calcium-sensing receptor and renal calcium excretion in patients with primary hyperparathyroidism. Eur J Endocrinol 2006; 155: 687-92.
Schwartz GG, John EM, Rowland G, Ingles SA. Prostate cancer in African-American men and polymorphism in the calcium-sensing receptor. Cancer Biol Ther 2010; 9: 994-9.
Han G, Wang O, Nie M, Zhu Y, Meng X, Hu Y, et al. Clinical phenotypes of Chinese primary hyperparathyroidism patients are associated with the calcium-sensing receptor gene R990G polymorphism. Eur J Endocrinol 2013; 169: 629-38.
Jeong S, Kim I-W, Oh K-H, Han N, Joo KW, Kim HJ, et al. Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Des Devel Ther 2016; 10: 2211-25.
Cole DE, Peltekova VD, Rubin LA, Hawker GA, Vieth R, Liew C, et al. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 1999; 353: 112-5.
Vezzoli G, Terranegra A, Arcidiacono T, Biasion R, Coviello D, Syren M, et al. R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int 2007; 71: 1155-62.
Eren P, Turan K, Berber I, Canbakan M, Kara M, Tellioglu G, et al. The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients. Clin Nephrol 2009; 72: 114-21
